Unit of Infectious Diseases/Venhälsan, Södersjukhuset, Stockholm, Sweden.
Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.
Infect Dis (Lond). 2021 Jan;53(1):1-8. doi: 10.1080/23744235.2020.1831696. Epub 2020 Oct 12.
Effective antiretroviral treatment of HIV-1, defined as continuously undetectable virus in blood, has substantial effects on the infectiousness and spread of HIV.
This paper outlines the assessment of the Swedish Reference Group for Antiviral Therapy (RAV) and Public Health Agency of Sweden regarding contagiousness of HIV-infected persons on antiretroviral therapy (ART). The expert group concludes that there is no risk of transmission of HIV during vaginal or anal intercourse if the HIV-infected person fulfils the criteria for effective ART. The effective antiretroviral therapy (ART) for HIV-1 infection has dramatically reduced the morbidity and mortality among people who live with HIV. ART also has a noticeable effect on the infectiousness and on the spread of the disease in society. Knowledge about this has grown gradually. For ART to be regarded effective, the level of the HIV RNA in the plasma should be repeatedly and continuously undetectable and the patient should be assessed as continually having high adherence to treatment. Based on available knowledge the Swedish Reference Group for Antiviral Therapy (RAV) and the Public Health Agency of Sweden make the following assessment: There is no risk of HIV transmission during vaginal or anal intercourse if the HIV positive person fulfils the criteria for effective treatment. This includes intercourse where a condom is not used. However, there are a number of other reasons for recommending the use of condoms, primarily to protect against the transmission of other STIs (sexually transmitted infections) and hepatitis, as well as unwanted pregnancy. The occurrence of other STIs does not affect the risk of HIV transmission in persons on effective ART. It is plausible that the risk for transmission of HIV infection between people who inject drugs and share injection equipment is reduced if the individual with HIV is on effective ART, but there are no studies that directly show this. The risk of transmission from mother to child during pregnancy, labour and delivery is very low if the mother's treatment is initiated well before delivery and if the treatment aim of undetectable virus levels is attained. This is dependent on healthcare services being aware of the mother's HIV infection at an early stage. In most contacts with health and medical care, including dental care, the risk of transmission is not significant if the patient is on effective treatment, but the risk may remain, although considerably reduced, in more advanced interventions such as surgery. When an incident with risk of transmission occurs, the patient must always inform those potentially exposed about his or her HIV infection.
有效的抗逆转录病毒治疗 HIV-1(定义为血液中持续无法检测到病毒)对 HIV 的传染性和传播有实质性影响。
本文概述了瑞典抗病毒治疗参考小组(RAV)和瑞典公共卫生署对接受抗逆转录病毒治疗(ART)的 HIV 感染者传染性的评估。专家组得出结论,如果 HIV 感染者符合有效 ART 的标准,那么通过阴道或肛门性交传播 HIV 的风险为零。有效的抗逆转录病毒治疗(ART)显著降低了 HIV 感染者的发病率和死亡率。ART 对社会疾病的传染性和传播也有显著影响。关于这方面的知识逐渐增加。为了使 ART 被认为有效,血浆中 HIV RNA 的水平应反复且持续无法检测到,并且应评估患者持续高度遵守治疗。基于现有知识,瑞典抗病毒治疗参考小组(RAV)和瑞典公共卫生署做出如下评估:如果 HIV 阳性者符合有效治疗标准,那么通过阴道或肛门性交传播 HIV 的风险为零。这包括不使用避孕套的性行为。然而,还有许多其他原因推荐使用避孕套,主要是为了防止其他性传播感染(STIs)和肝炎以及意外怀孕的传播。在接受有效 ART 的人中,其他 STIs 的发生并不影响 HIV 传播的风险。如果 HIV 感染者接受有效的 ART,那么他们之间通过共用注射设备进行静脉注射毒品传播 HIV 感染的风险可能会降低,但没有研究直接证明这一点。如果母亲在分娩前尽早开始治疗,并且达到病毒水平无法检测到的治疗目标,那么在怀孕期间、分娩期间和分娩过程中母婴传播 HIV 的风险非常低。这取决于医疗保健服务能够在早期发现母亲的 HIV 感染。在大多数与健康和医疗保健相关的接触中,包括牙科保健,只要患者接受有效的治疗,传播的风险就不显著,但在更先进的干预措施(如手术)中,风险仍然存在,尽管大大降低。如果发生有传播风险的事件,患者必须始终将其 HIV 感染情况告知那些可能被暴露的人。